<DOC>
	<DOCNO>NCT01408537</DOCNO>
	<brief_summary>Japanese encephalitis ( JE ) main cause viral encephalitis many country Asia include Thailand . Estimated annual mortality range from10,000-15,000 death , total number clinical case 50,000 . Of case , 50 % result permanent neuropsychiatric sequela . The disease occur mostly among child age &lt; 10 year . There specific antiviral treatment JE . Vaccination single important control measure . This study aim evaluate immunogenicity safety inactivate Vero cell derive JE vaccine ( Beijing P-3 strain ) produce Liaoning Cheng Da Biotechnology Co. , Ltd , China `` JEVAC '' Thai child . 152 healthy Thai child age 1-3 year vaccinate `` JEVAC '' dose 0.5 mL . subcutaneously Day 0 , 1-4 week later booster vaccination one year ( totally 3 dos ) . Two mL . blood drawn Day 0 , 4 week second dose , one year booster vaccination day 4 week booster ( totally 8 mL . 13 month study period ) determination JE neutralizing antibody ( PRNT50 ) use Beijing P3 strain . Adverse event observe 28 day vaccination . Serious adverse event observe throughout study period .</brief_summary>
	<brief_title>Immunogenicity Safety Inactivated Vero Cell Derived Japanese Encephalitis Vaccine Thai Children</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy Thai child age 1 3 year 2 . No previous history JE vaccination 3 . Available visited schedule study period . 4 . Written inform consent sign parent guardian 1 . Known serious underlying disease nervous system , heart , kidney liver disease . 2 . Known hypersensitivity JE vaccine composition human albumin , dextran 40 , etc . 3 . Previous history JE disease . 4 . Receive blood component within past 3 month , 5 . Known history immunocompromised condition HIV/AIDS , malignancy . 6 . Under treatment immunosuppressive drug systemic corticosteroid antineoplastic drug . 7 . Febrile illness ( temperature ≥37.5°C ) acute illness/infection day vaccination 8 . Plan leave study area end study period . 9 . Participating clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>inactivate Japanese encephalitis vaccine</keyword>
	<keyword>vero cell</keyword>
	<keyword>child</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
</DOC>